Press releases

December

• 12/24/20 - Transparency notification received from CPH Banque
• 12/24/20 - Bone Therapeutics: Information on the total number of voting rights and shares (December 2020)
• 12/22/20 - Bone Therapeutics completes recruitment and patient treatment in JTA-004 pivotal Phase III knee osteoarthritis study
• 12/16/20 - Bone Therapeutics announces closing of private placement
• 12/11/20 - Bone Therapeutics announces pricing of private placement

November

• 11/16/20 - Bone Therapeutics announces completion of the acquisition of its cell therapy manufacturing subsidiary SCTS by Catalent
• 11/10/20 - Bone Therapeutics, Cerhum, 3D-Side, mSKIL and IREC awarded €3M in BioWin supported funding to develop personalized, tissue engineered bone implants

October

• 10/30/20 - Bone Therapeutics Provides Third Quarter 2020 Business Update
• 10/29/20 - Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB
• 10/23/20 - Transparency notification received from S.R.I.W. SA and Sofipôle SA
• 10/23/20 - Bone Therapeutics: Information on the total number of voting rights and shares (October 2020)
• 10/20/20 - Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III pivotal knee osteoarthritis study
• 10/14/20 - Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion
• 10/12/20 - Bone Therapeutics to present at 2020 Virtual Cell & Gene Meeting on the Mesa
• 10/5/20 - Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia

September

• 9/9/20 - Information on the total number of voting rights and shares

August

• 8/26/20 - Bone Therapeutics reports half year 2020 results
• 8/20/20 - Bone Therapeutics announces expansion of its pipeline supported by funding from the Walloon Region
• 8/13/20 - Bone Therapeutics receives EUR 1.0 million to advance ongoing JTA-004 phase III knee osteoarthritis study

June

• 6/11/20 - Bone Therapeutics announces Annual General Meeting results and confirms outlook for 2020

May

• 5/29/20 - Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA
• 5/29/20 - Bone Therapeutics: Information on the total number of voting rights and shares (May 2020)
• 5/18/20 - Bone Therapeutics treats first patients in pivotal JTA-004 phase III knee osteoarthritis study
• 5/11/20 - Bone Therapeutics to host Annual Ordinary General Meeting on 10 June 2020
• 5/7/20 - Bone Therapeutics raises additional EUR 4.0 million, with total of EUR 15 million committed, providing runway into Q2 2021
• 5/6/20 - Bone Therapeutics Provides First Quarter 2020 Business Update

April

• 4/29/20 - Bone Therapeutics secures EUR 11.0 million financing
• 4/3/20 - Bone Therapeutics: Information on the total number of voting rights and shares (March 2020)

March

• 3/26/20 - Bone Therapeutics appoints Stefanos Theoharis as Chief Business Officer
• 3/23/20 - Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates
• 3/11/20 - Bone Therapeutics announces 2019 full year results

February

• 2/28/20 - Bone Therapeutics: Information on the total number of voting rights and shares (February 2020)
• 2/11/20 - Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at the Annual Meeting of the ORS

January

• 1/31/20 - Bone Therapeutics: Information on the total number of voting rights and shares (January 2020)
• 1/22/20 - Bone Therapeutics announces 2020 business outlook and reports year-end 2019 cash position
• 1/9/20 - Bone Therapeutics announces attendance at the 38th Annual J.P. Morgan Healthcare Conference

December

• 12/30/19 - Bone Therapeutics: Information on the total number of voting rights and shares (December 2019)
• 12/20/19 - Bone Therapeutics advances JTA-004 into pivotal Phase III study
• 12/19/19 - Bone Therapeutics announces the appointment of Dr. Miguel Forte as CEO to lead the Company into the next phase of development
• 12/9/19 - Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA

November

• 11/29/19 - Bone Therapeutics: Information on the total number of voting rights and shares (November 2019)
• 11/25/19 - Bone Therapeutics: The preliminary documents for the Extraordinary General Shareholder Meeting on 12 December 2019 have been made available
• 11/6/19 - Bone Therapeutics Reports Financial Results for the First Nine Months of 2019 and Provides Third Quarter 2019 Business Update

October

• 10/22/19 - Bone Therapeutics: The preliminary documents for the Extraordinary General Shareholder Meeting on 22 November 2019 have been made available
• 10/3/19 - Bone Therapeutics: Information on the total number of voting rights and shares (September 2019)

September

• 9/27/19 - Bone Therapeutics to present data from its Phase II/III trial with JTA-004 at the 2nd World Congress on Rheumatology & Orthopedics
• 9/9/19 - Bone Therapeutics: Information on the total number of voting rights and shares (August 2019)

August

• 8/30/19 - Bone Therapeutics reports half year 2019 results
• 8/28/19 - Bone Therapeutics to report half year 2019 results on 30 August 2019

July

• 7/30/19 - Bone Therapeutics: Information on the total number of voting rights and shares (July 2019)
• 7/11/19 - Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA
• 7/4/19 - Bone Therapeutics: Transparency notification received from Mr. J. Reymann
• 7/2/19 - Bone Therapeutics: Information on the total number of voting rights and shares

June

• 6/27/19 - Bone Therapeutics successfully raises EUR 8.5 million
• 6/27/19 - Bone Therapeutics to raise capital through private placement of new shares and issuance of non-dilutive subordinated bonds
• 6/21/19 - Bone Therapeutics: Information on the total number of voting rights and shares (June 2019)
• 6/13/19 - Bone Therapeutics’ allogeneic cell therapy product ALLOB meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion
• 6/13/19 - Bone Therapeutics’ allogeneic cell therapy product ALLOB meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion
• 6/12/19 - Bone Therapeutics announces results of Annual General Meeting

May

• 5/31/19 - Bone Therapeutics to participate in upcoming conferences
• 5/29/19 - Bone Therapeutics: Information on the total number of voting rights and shares (May 2019)
• 5/24/19 - Bone Therapeutics to present data at TERMIS European Chapter Meeting 2019
• 5/24/19 - The preliminary documents for the Extraordinary General Shareholder Meeting on 12 June 2019 have been made available
• 5/10/19 - The preliminary documents for the Annual Ordinary General Shareholder Meeting on 12 June 2019 have been made available
• 5/7/19 - Bone Therapeutics Provides First Quarter 2019 Business Update

April

• 4/29/19 - Bone Therapeutics: Information on the total number of voting rights and shares (April 2019)
• 4/25/19 - Bone Therapeutics announces publication of Annual Report 2018 and Extraordinary General Meeting on 23 May 2019
• 4/23/19 - The preliminary documents for the Extraordinary General Shareholder Meeting on 23 May 2019 have been made available

March

• 3/28/19 - Bone Therapeutics: Information on the total number of voting rights and shares (March 2019)
• 3/18/19 - Bone Therapeutics to present at Herbert Fleisch / IFMRS Workshop
• 3/12/19 - Bone Therapeutics appoints Olivier Godeaux as Chief Medical Officer and Benoit Moreaux as Chief Scientific and Technology Officer
• 3/5/19 - Bone Therapeutics: Information on the total number of voting rights and shares (February 2019)
• 3/1/19 - Bone Therapeutics announces 2018 full year results

February

• 2/25/19 - Bone Therapeutics Notice of Full Year 2018 Results
• 2/5/19 - Bone Therapeutics to present at the Annual Meeting of the Orthopaedic Research Society (ORS)

January

• 1/30/19 - Bone Therapeutics: Information on the total number of voting rights and shares (January 2019)
• 1/30/19 - Bone Therapeutics holds successful event to highlight strength of cell and gene therapy in Wallonia
• 1/22/19 - Bone Therapeutics announces 2019 business outlook and reports year-end 2018 cash position

December

• 12/24/18 - Bone Therapeutics: Information on the total number of voting rights and shares (December 2018)
• 12/11/18 - Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA

November

• 11/29/18 - Bone Therapeutics: Information on the total number of voting rights and shares (November 2018)
• 11/7/18 - Bone Therapeutics Business Update for Third Quarter 2018
• 11/6/18 - Bone Therapeutics announces conclusions from interim analysis of Phase III PREOB study in hip osteonecrosis

October

• 10/29/18 - Bone Therapeutics announces appointment of Linda Lebon as Chief Regulatory Officer
• 10/25/18 - Bone Therapeutics: Information on the total number of voting rights and shares (October 2018)
• 10/17/18 - Single intra-articular injection of viscosupplement JTA-004 delivered higher pain reduction than the reference in first study in knee osteoarthritis

September

• 9/27/18 - Bone Therapeutics: Information on the total number of voting rights and shares (2018-09)
• 9/24/18 - Bone Therapeutics to present at 26th Annual Meeting of the European Orthopaedic Research Society
• 9/14/18 - Bone Therapeutics announces final results from Phase I/IIA ALLOB delayed-union fracture study
• 9/3/18 - Bone Therapeutics: Information on the total number of voting rights and shares

August

• 8/30/18 - Bone Therapeutics Announces H1 Results for 2018
• 8/8/18 - Bone Therapeutics Notice of Half Year 2018 Results

July

• 7/20/18 - Bone Therapeutics: Information on the total number of voting rights and shares

June

• 6/21/18 - The preliminary documents for the Extraordinary General Shareholder Meeting on 9 July 2018 have been made available
• 6/14/18 - Bone Therapeutics announces results of Annual General Meeting
• 6/11/18 - Bone Therapeutics: Information on the total number of voting rights and shares

May

• 5/28/18 - Bone Therapeutics: Information on the total number of voting rights and shares
• 5/9/18 - The preliminary documents for the Annual Ordinary and the Extraordinary General Shareholder Meeting on 13 June 2018 have been made available
• 5/4/18 - Bone Therapeutics Business Update for First Quarter 2018
• 5/4/18 - Bone Therapeutics: Information on the total number of voting rights and shares

April

• 4/26/18 - Bone Therapeutics Strengthens Board with the Appointment of Claudia D'Augusta as Non-Executive Director
• 4/25/18 - Bone Therapeutics Reports Full Year 2017 Results
• 4/4/18 - Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA

March

• 3/21/18 - Bone Therapeutics: Information on the total number of voting rights and shares
• 3/7/18 - Bone Therapeutics Successfully Raises EUR 19.45 Million of Commitments in Convertible Bond Placement
• 3/7/18 - Bone Therapeutics Announces Private Placement of Convertible Bonds

February

• 2/20/18 - Bone Therapeutics strengthens Board with the appointment of Jean Stéphenne as Chairman
• 2/19/18 - Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB

January

• 1/23/18 - Bone Therapeutics provides business outlook and announces its financial calendar for 2018
• 1/19/18 - Bone Therapeutics réaffirme son éligibilité au PEA-PME pour 2018

December

• 12/15/17 - Bone Therapeutics Provides Update on Equity Placement
• 12/14/17 - Bone Therapeutics Launches Equity Placement
• 12/11/17 - Bone Therapeutics and Cellthera Pharm LLC announce intention to collaborate and Bone Therapeutics provides overview of its pipeline

November

• 11/9/17 - Bone Therapeutics Business Update for Third Quarter 2017

October

• 10/24/17 - Bone Therapeutics to participate in upcoming key investor and partnering conferences in Q4 2017
• 10/13/17 - The preliminary documents for the Extraordinary General Shareholder Meeting on 30 October 2017 have been made available

September

• 9/22/17 - Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB in Japan
• 9/20/17 - Bone Therapeutics announces all patients meet primary endpoint in ALLOB Phase I/IIA delayed-union study interim analysis
• 9/14/17 - Bone Therapeutics reports strong interim results from ALLOB Phase IIA spinal fusion study
• 9/4/17 - The preliminary documents for the Extraordinary General Shareholder Meeting on 5 October 2017 have been made available

August

• 8/31/17 - Bone Therapeutics announces H1 results for 2017
• 8/31/17 - Bone Therapeutics appoints Jean-Luc Vandebroek as Chief Financial Officer
• 8/24/17 - Bone Therapeutics Notice of Half Year 2017 Results

July

• 7/3/17 - Bone Therapeutics strengthens board of directors

June

• 6/26/17 - Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell  therapy platform
• 6/8/17 - Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB

May

• 5/29/17 - Bone Therapeutics strengthens Board with the appointments of Steve Swinson and Damian Marron as Non-Executive Directors
• 5/11/17 - Bone Therapeutics Business Update for First Quarter 2017

April

• 4/26/17 - Bone Therapeutics: The preliminary documents for the Annual General Shareholder Meeting on 26 May 2017 have been made available
• 4/25/17 - Bone Therapeutics announces the publication of its Annual Report 2016

March

• 3/16/17 - Bone Therapeutics Reports Full Year 2016 Results
• 3/10/17 - Bone Therapeutics to participate in upcoming key investor conferences
• 3/9/17 - Bone Therapeutics completes recruitment of 16 patients in ALLOB Phase I/IIA delayed-union study
• 3/6/17 - Bone Therapeutics Strengthens Clinical Development Leadership with Appointment of Dr. Miguel Forte as Chief Medical Officer
• 3/3/17 - Bone Therapeutics Notice of Full Year 2016 Results

January

• 1/20/17 - Bone Therapeutics réaffirme son éligibilité au PEA-PME pour 2017
• 1/17/17 - Bone Therapeutics Provides Business Update for Q4 2016
• 1/6/17 - Bone Therapeutics Granted EUR 2.3 Million in Non-Dilutive Funding by the Walloon Region

December

• 12/21/16 - Bone Therapeutics announces its financial calendar for 2017

November

• 11/8/16 - Bone Therapeutics Business Update for Third Quarter 2016
• 11/2/16 - Bone Therapeutics Notice of Q3 2016 Results - Results to be announced on 8 November 2016

October

• 10/11/16 - Enrico Bastianelli to stand down as CEO of Bone Therapeutics
• 10/11/16 - Transparency notification received from Theodorus II SA
• 10/5/16 - Bone Therapeutics reports positive efficacy data for the ALLOB® Phase IIA spinal fusion trial

September

• 9/15/16 - Bone Therapeutics receives positive ruling on Belgian Patent Income Deduction

August

• 8/30/16 - Bone Therapeutics announces H1 results for 2016
• 8/25/16 - Bone Therapeutics Half Year 2016 Results to be announced on 30 August 2016

June

• 6/8/16 - Bone Therapeutics demonstrates superiority of PREOB® in Phase IIB osteonecrosis study presented at EULAR
• 6/3/16 - Bone Therapeutics celebrates ten years of innovation in bone cell therapy

May

• 5/19/16 - Bone Therapeutics to enhance value of its severe osteoporosis program by transitioning to allogeneic development
• 5/17/16 - Bone Therapeutics announces further positive efficacy in ALLOB® Phase I/IIA delayed-union fracture trial
• 5/10/16 - Bone Therapeutics Provides Business Update for the First Quarter of 2016
• 5/3/16 - Bone Therapeutics completes recruitment of its ALLOB®Phase IIA spinal fusion study

April

• 4/26/16 - The preliminary documents for the Annual General Shareholder Meeting on 26 May 2016 have been made available
• 4/14/16 - Bone Therapeutics announces the publication of its Annual Report 2015

March

• 3/29/16 - Bone Therapeutics Reports Full Year 2015 Results
• 3/29/16 - Bone Therapeutics reports initial efficacy results from its PREOB® Phase IIA trial in severe osteoporosis
• 3/16/16 - Bone Therapeutics Notice of Full Year 2015 Results: Results to be announced on 29 March 2016

February

• 2/24/16 - Bone Therapeutics presents ALLOB® pre-clinical and early clinical efficacy data in spinal fusion at the Clinical Applications of Stem Cells Conference
• 2/17/16 - Bone Therapeutics Provides Business Update for the Fourth Quarter of 2015
• 2/17/16 - Bone Therapeutics treats 12 patients without safety concerns in ALLOB® Phase IIA spinal fusion trial
• 2/2/16 - Bone Therapeutics extends Kasios collaboration

January

• 1/20/16 - Bone Therapeutics réaffirme son éligibilité au PEA-PME pour 2016
• 1/18/16 - Bone Therapeutics expands its delayed-union program with ALLOB® into multiple fractures
• 1/13/16 - Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2016
• 1/5/16 - Bone Therapeutics Granted an Additional EUR 2 Million in Non-Dilutive Funding by the Walloon Region

December

• 12/23/15 - Bone Therapeutics announces its financial calendar for 2016
• 12/15/15 - Bone Therapeutics completes recruitment of the first half of patients in ALLOB® Phase IIA spinal fusion trial
• 12/11/15 - ALLOB® Delayed-Union Program Awarded at Cells Orthopedics Conference

November

• 11/30/15 - Bone Therapeutics Awarded EUR 3 million in Funding to Support New Research Projects
• 11/18/15 - Bone Therapeutics Provides Business Update for the Third Quarter of 2015
• 11/12/15 - Bone Therapeutics’ ALLOB® receives Orphan Drug Designation for Osteogenesis Imperfecta from the EMA and FDA
• 11/9/15 - Bone Therapeutics Appoints Thomas Lienard as Chief Business Officer

October

• 10/22/15 - Transparency notification received from S.R.I.W. SA & Sofipôle SA
• 10/13/15 - Bone Therapeutics to participate in key investor conferences in Q4 2015

September

• 9/28/15 - Bone Therapeutics treats first patients in pioneering trial for minimally invasive treatment of failed spinal fusion
• 9/22/15 - Bone Therapeutics announces half-year results for 2015
• 9/21/15 - Bone Therapeutics Notice of Half Year Results 2015
• 9/7/15 - Bone Therapeutics treats second patient cohort in ALLOB® Phase I/IIA delayed-union fracture trial

June

• 6/22/15 - Bone Therapeutics reports first results of its Phase IIA trial for PREOB® in severe osteoporosis

May

• 5/15/15 - Bone Therapeutics Provides Business Update for the First Quarter 2015

April

• 4/28/15 - Bone Therapeutics Reports 2014 Financial and Operational Results
• 4/24/15 - Bone Therapeutics officially opens its new headquarters in Gosselies
• 4/13/15 - Bone Therapeutics Establishes US Subsidiary

March

• 3/23/15 - Bone Therapeutics treats first patients in ALLOB® Phase IIA spinal fusion trial
• 3/2/15 - Bone Therapeutics accelerates its ALLOB® Phase I/IIA Delayed-Union trial

February

• 2/19/15 - Information on the total number of voting rights and shares
• 2/18/15 - Bone Therapeutics announces its financial calendar for 2015
• 2/17/15 - Transparency notification received from S.R.I.W. & Sofipôle, Mr J. Reymann, SFPI SA and Theodorus II SA
• 2/16/15 - Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2015
• 2/11/15 - Full exercise of Over-allotment Option: Total proceeds from the Initial Public Offering increased to €37 million
• 2/4/15 - Bone Therapeutics raises EUR32.2M in a 2.5x oversubscribed successful Initial Public Offering on Euronext Brussels and Euronext Paris

January

• 1/21/15 - Bone Therapeutics Launches its Initial Public Offering on Euronext Brussels and Euronext Paris
• 1/19/15 - Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB® Phase I/IIA Delayed-Union Trial
• 1/16/15 - Bone Therapeutics Announces Intention to Launch an Initial Public Offering on Euronext Brussels and Euronext Paris
• 1/5/15 - Bone Therapeutics Expands Product Portfolio with New Research into Innovative Combined Cell-Matrix Product

December

• 12/4/14 - Bone Therapeutics Authorised to Enrol patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB®

November

• 11/17/14 - Bone Therapeutics and Kasios to collaborate on novel product for the optimisation of spinal fusion procedures

October

• Bone Therapeutics extends ALLOB® phase I/IIa trial to Germany

September

• Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion
• Bone Therapeutics supports pioneering research by backing projects vital to regenerative medicine research (EN)

July

• Bone Therapeutics and Partners awarded over €0.5 million M-ERA.net research funding to develop 3-D patient-tailored bone tissue engineered products

June

• Bone Therapeutics Starts Patient Treatment in First Ever Clinical Trial with Allogeneic Bone Cell Therapy Product

January

• Bone Therapeutics to present at Biotech Showcase in San Francisco on Tuesday 14 January, 2014 at 10.15am

December

• Bone Therapeutics and partners awarded highly competitive €3.8 million Marie Curie research grant

November

• Bone Therapeutics’ pivotal phase III osteonecrosis trial with PREOB® hits a new milestone - 30 centres across Europe now active
• Bone Therapeutics treats first patients in PREOB® pivotal phase IIb/III trial for the treatment of non-union fractures

October

• Bone Therapeutics receives clearance for ALLOB® phase I/IIa trial

September

• Bone Therapeutics Appoints Wim Goemaere as Chief Financial Officer

June

• Establishment of the Walloon Cell Therapy Platform: The platform aims to produce cell therapy medicines on a large scale
• Fondation de la Plateforme Wallonne de Thérapie Cellulaire: La plateforme vise à produire les médicaments de thérapie cellulaire à grande échelle

April

• Bone Therapeutics and Erasme University Start Phase IIa Trial in Osteoporosis with its Cell Therapy Product PREOB®
• Bone Therapeutics to Present at Upcoming Investor Conferences

March

• Bone Therapeutics Awarded Manufacturing Authorisation and European Approval to Produce Allogeneic Bone Cell Therapy Products

February

• Bone Therapeutics Invests in Cell Therapy Manufacturing Facility

January

• Bone Therapeutics Raises €7.7 Million in Series D Fundraising

October

• Bone Therapeutics receives clearance for its pivotal phase III osteonecrosis trial with PREOB® in Europe and treats the first patients in the study
• Bone Therapeutics reçoit l'approbation des autorités et traite les premiers patients dans son étude clinique de phase III en ostéonécrose avec son produit PREOB®

February

• Bone Therapeutics lève 9,5M €

June

• Bone Therapeutics entre dans une nouvelle Phase de son développement Industriel